<DOC>
	<DOCNO>NCT01586442</DOCNO>
	<brief_summary>In proposal , investigator examine whether selectivity eplerenone MR translate well glucose metabolic profile compare spironolactone patient HF glucose intolerance type 2 diabetes . In addition , investigator also compare impact two agent change concentration establish prognostic biomarkers neurohormonal activation extracellular matrix turnover .</brief_summary>
	<brief_title>Comparison Eplerenone Versus Spironolactone Heart Failure Patients With Glucose Intolerance Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<criteria>1 . Male female least 18 year old . 2 . Symptomatic HF correspond NYHA class IIIV symptoms least 4 week prior randomization . 3 . A diagnosis 1 ) impair glucose tolerance describe overnight fast blood glucose 5.6 6.9 mmol/L two occasion ; 2 ) type 2 diabetes define overnight fast blood glucose 7.0 mmol/L two occasion ; HbA1c equal high 6.5 % two occasion ; history type II diabetes treated hypoglycemic agent . 4 . LVEF equal low 40 % document , contrast ventriculography , magnetic resonance imaging , radionuclide ventriculography quantitative echocardiography within previous 12 month cardiac event occur since measurement LVEF . The recent measurement use . 5 . Treatment optimal stable dose ACE inhibitor ( ARB ) least 4 week prior enrolment study . In addition , patient treat stable dose betablockers least 4 week prior enrolment study . Patients incapable tolerate bisoprolol , carvedilol metoprolol allow within trial . 6 . Informed consent must obtain study specific procedure perform 1 . Current treatment combination ARB , ACE renin inhibitor . 2 . Type 1 diabetes 3 . Known intolerance allergy eplerenone spironolactone , include gynecomastia spironolactone . 4 . Estimated GFR &lt; 30 mL/min/1.73 m2 calculate use MDRD equation ( Appendix 1 ) . 5 . Current serum potassium high 5.0 mmol/L ( high 5.0 mEq/L ) . 6 . Current symptomatic hypotension and/or systolic B.P . &lt; 90 mmHg . 7 . Persistent systolic diastolic hypertension ( systolic &gt; 170 mmHg diastolic &gt; 100 mmHg despite use antihypertensive therapy ) . 8 . HF secondary follow condition : hemodynamically significant primary stenotic valvular cardiomyopathy , isolate right side CHF , non cardiac disease ( e.g . uncorrected thyroid disease ) , pericardial disease , complex congenital heart disease , myocarditis . 9 . Decompensated heart failure describe hospitalization I.V . administration medication emergency room heart failure clinic within 4 week ( ex . : diuretic , inotropes , vasodilatators ) 10 . Current treatment insulin 11 . Stroke , acute coronary syndrome , PCI within last 4 week randomization . 12 . Cardiac surgery within 3 month . 13 . Significant liver disease ( ALT x 3 time limit normal ) . 14 . Planned cardiac surgery expect perform within next 6 month . 15 . Previous heart transplant heart transplant expect perform within next 6 month . 16 . Presence noncardiac disease likely significantly shorten life expectancy &lt; 1 year . 17 . Pregnant lactate woman woman childbearing potential protected pregnancy accept method contraception , oral contraceptive pill , intrauterine device surgical sterilization ( woman childbearing potential must negative pregnancy test randomization ) . 18 . Any condition opinion investigator would jeopardize evaluation efficacy safety associate poor adherence protocol . 19 . Treatment investigational agent device within 4 week randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>